Clinical comparison in the remote management of bronchial asthma during the COVID-19 pandemic between two controller therapies: Fluticasone and beclomethasone
DOI:
https://doi.org/10.35663/amp.2023.404.2692Keywords:
Asthma, COVID-19, Glucocorticoids, Remote Consultation, Fluticasone, BeclomethasoneAbstract
Objective: To compare the level of asthma control using the Asthma Control Test (ACT) and clinical manifestations in two groups of patients treated with different inhaled corticosteroids (ICG).
Materials and methods: Descriptive, observational and prospective study in which the level of asthma control was recorded in 521 children in the asthma programme of Hospital III Yanahuara (Arequipa, Peru), during the period from June 2020 to December 2021, by means of remote consultation using the ACT and the collection of clinical findings (daytime and night-time symptoms, emergency visits and the use of beta-2 agonist bronchodilators), at two points in time during the COVID-19 pandemic.
Results: Both groups had optimal control at baseline and at the end of the study, with a significant improvement in the last control (P < 0.05). In clinical manifestations there was no statistical difference (P > 0.05) in both controls. The mean ACT level of Fluticasone at discharge was significantly superior to Beclomethasone (P = 0.03).
Conclusions: Teleconsultation is an effective tool for monitoring chronic diseases such as asthma. Both Fluticasone and Beclomethasone achieved optimal disease control, highlighting that the true determinant of good control is the continuous use of any ICG. However, a significant statistical difference was found in favour of Fluticasone; nevertheless, due to its lower price, the cost-effectiveness ratio favours Beclomethasone as a cost-effective and efficient option for optimal asthma control.
Downloads
Downloads
Published
Issue
Section
License
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
How to Cite
